INmune Bio Inc. Unveils Promising MINDFuL Trial Results for Alzheimer's Treatment XPro™ at AAIC 2025

Reuters

07/29

<a href="https://laohu8.com/S/INMB">INmune Bio Inc</a>. Unveils Promising MINDFuL Trial Results for Alzheimer's Treatment XPro™ at AAIC 2025

INmune Bio Inc. (NASDAQ: INMB) has announced the upcoming release of a video detailing additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor. This video will be available on the company's YouTube Channel following the conclusion of the Alzheimer's Association International Conference $(AAIC)$ in Toronto, Canada. The video presentation will provide a comprehensive overview of the clinical insights shared during AAIC, focusing on the evaluation of XPro™ within the MINDFuL study design and its significance for early-stage Alzheimer's disease therapies. The presentation at AAIC is scheduled for July 29, 2025, from 2:00 to 3:30 PM ET, with the video being made available at 4 PM ET on July 31, 2025. The MINDFuL trial is a double-blind, Phase 2 proof-of-concept study that has demonstrated consistent benefits in slowing cognitive decline in a subpopulation of patients with early-stage Alzheimer's disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9502079-en) on July 29, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2555058156"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555058156\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555058156?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-29 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555058156","market":"us","top_or_hot":-1,"title":"INmune Bio Inc. Unveils Promising MINDFuL Trial Results for Alzheimer's Treatment XPro™ at AAIC 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/INMB\">INmune Bio Inc</a>. Unveils Promising MINDFuL Trial Results for Alzheimer's Treatment XPro™ at AAIC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        INmune Bio Inc. (NASDAQ: INMB) has announced the upcoming release of a video detailing additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor. This video will be available on the company's YouTube Channel following the conclusion of the Alzheimer's Association International Conference <a href=\"https://laohu8.com/S/AAIC\">$(AAIC)$</a> in Toronto, Canada. The video presentation will provide a comprehensive overview of the clinical insights shared during AAIC, focusing on the evaluation of XPro™ within the MINDFuL study design and its significance for early-stage Alzheimer's disease therapies. The presentation at AAIC is scheduled for July 29, 2025, from 2:00 to 3:30 PM ET, with the video being made available at 4 PM ET on July 31, 2025. The MINDFuL trial is a double-blind, Phase 2 proof-of-concept study that has demonstrated consistent benefits in slowing cognitive decline in a subpopulation of patients with early-stage Alzheimer's disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9502079-en) on July 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INmune Bio Inc. Unveils Promising MINDFuL Trial Results for Alzheimer's Treatment XPro™ at AAIC 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINmune Bio Inc. Unveils Promising MINDFuL Trial Results for Alzheimer's Treatment XPro™ at AAIC 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-29 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/INMB\">INmune Bio Inc</a>. Unveils Promising MINDFuL Trial Results for Alzheimer's Treatment XPro™ at AAIC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        INmune Bio Inc. (NASDAQ: INMB) has announced the upcoming release of a video detailing additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor. This video will be available on the company's YouTube Channel following the conclusion of the Alzheimer's Association International Conference <a href=\"https://laohu8.com/S/AAIC\">$(AAIC)$</a> in Toronto, Canada. The video presentation will provide a comprehensive overview of the clinical insights shared during AAIC, focusing on the evaluation of XPro™ within the MINDFuL study design and its significance for early-stage Alzheimer's disease therapies. The presentation at AAIC is scheduled for July 29, 2025, from 2:00 to 3:30 PM ET, with the video being made available at 4 PM ET on July 31, 2025. The MINDFuL trial is a double-blind, Phase 2 proof-of-concept study that has demonstrated consistent benefits in slowing cognitive decline in a subpopulation of patients with early-stage Alzheimer's disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9502079-en) on July 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nNDLk25dL:1","article_id":"2555058156","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555058156","pubTimestamp":1753786890,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"INmune Bio Inc.  has announced the upcoming release of a video detailing additional findings from the Phase 2 MINDFuL trial evaluating XPro, a novel selective soluble TNF inhibitor. This video will be available on the company's YouTube Channel following the conclusion of the Alzheimer's Association International Conference  in Toronto, Canada. The video presentation will provide a comprehensive overview of the clinical insights shared during AAIC, focusing on the evaluation of XPro within the MINDFuL study design and its significance for early-stage Alzheimer's disease therapies. The presentation at AAIC is scheduled for July 29, 2025, from 2:00 to 3:30 PM ET, with the video being made available at 4 PM ET on July 31, 2025. The MINDFuL trial is a double-blind, Phase 2 proof-of-concept study that has demonstrated consistent benefits in slowing cognitive decline in a subpopulation of patients with early-stage Alzheimer's disease.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4112":"金融交易所和数据","INMB":"INmune Bio Inc","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所"},"translate_title":"INmune Bio Inc.公布了阿尔茨海默病治疗XPro的有希望的正念试验结果™在AAIC 2025","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INMB":0.9,"NDAQ":0.9},"content_text":"INmune Bio Inc. Unveils Promising MINDFuL Trial Results for Alzheimer's Treatment XPro™ at AAIC 2025\n    \n\n        INmune Bio Inc. (NASDAQ: INMB) has announced the upcoming release of a video detailing additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor. This video will be available on the company's YouTube Channel following the conclusion of the Alzheimer's Association International Conference $(AAIC)$ in Toronto, Canada. The video presentation will provide a comprehensive overview of the clinical insights shared during AAIC, focusing on the evaluation of XPro™ within the MINDFuL study design and its significance for early-stage Alzheimer's disease therapies. The presentation at AAIC is scheduled for July 29, 2025, from 2:00 to 3:30 PM ET, with the video being made available at 4 PM ET on July 31, 2025. The MINDFuL trial is a double-blind, Phase 2 proof-of-concept study that has demonstrated consistent benefits in slowing cognitive decline in a subpopulation of patients with early-stage Alzheimer's disease.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9502079-en) on July 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}